Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 — SUBSEQUENT EVENTS Subsequent to September 30, 2023, the Company entered into Addendum to Revenue Purchase Agreement with a third party pursuant to which it sold $1,377,500 of future accounts receivable in exchange for net cash proceeds of $950,000. Under the Addendum, payments of $81,029 are due weekly until the initial loan converts to a term loan in the principal amount of $1.2 million. The portion of net proceeds from the transaction were used to repay a $500,000 promissory note issued in February 2023 and for working capital and general corporate purposes.

SUBSEQUENT EVENTS

9 Months Ended

Sep. 30, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 13 — SUBSEQUENT EVENTS

Subsequent to September 30, 2023, the Company entered into Addendum to Revenue Purchase Agreement with a third party pursuant to which it sold $1,377,500 of future accounts receivable in exchange for net cash proceeds of $950,000. Under the Addendum, payments of $81,029 are due weekly until the initial loan converts to a term loan in the principal amount of $1.2 million. The portion of net proceeds from the transaction were used to repay a $500,000 promissory note issued in February 2023 and for working capital and general corporate purposes.